论文部分内容阅读
就应用免疫组织化学方法对正常肾组织和肾癌组织中Ｃ－ｍｙｃ蛋白和增殖细胞核抗原（ＰＣＡＮ）表达水平进行检测。结果在５例正常肾组织中未见Ｃ－ｍｙｃ和ＰＣＮＡ的表达。４５例肾癌中Ｃ－ｍｙｃ和ＰＣ－ＮＡ蛋白阳性表达率他别为２６．７％（１２／４５）和４４．％（２０／４５），阳性表的ＰＣＮＡ和Ｃ－ｍｙｃ蛋白均定位于肾癌细胞核上，并且ＰＣＮＡ和Ｃ－ｍｙｃ蛋白阳性表达率与肾癌的病理分级，临床分期及患者术后生存期有关。提示Ｃ－ｍｙｃ和ＰＣＮＡ蛋白阳性表达参入了肾癌发生和发展，并且有可能成为肾癌预后的客观指标之一。
Immunohistochemistry was used to detect the expression of C-myc and PCAN in normal kidney and renal cell carcinoma tissues. Results No expression of C-myc and PCNA was found in 5 normal renal tissues. The positive rates of C-myc and PCNA in 45 cases of renal cell carcinoma were 26.7% (12/45) and 44% respectively. % (20/45). The positive expression rates of PCNA and C-myc were both located in the nucleus of renal cell carcinoma, and the positive rates of PCNA and C-myc protein were related to the pathological grade, clinical stage and survival time . It is suggested that the positive expression of C-myc and PCNA may be involved in the occurrence and development of renal cell carcinoma, and may be one of the objective indicators of the prognosis of renal cell carcinoma.